Dexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways.

Ettcheto Arriola, Miren; Sánchez-López, E. (Elena); Pons, Laura; Busquets Figueras, Oriol; Olloquequi, Jordi; Beas Zárate, Carlos; Pallàs i Llibería, Mercè, 1964-; García López, María Luisa; Auladell i Costa, M. Carme; Folch, Jaume; Camins Espuny, Antoni

Dexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways.

The aim of the present study is to elucidate the neuronal pathways associated to NSAIDs causing a reduction of the risk and progression of Alzheimer's disease. The research was developed administering the active enantiomer of ibuprofen, dexibuprofen (DXI), in order to reduce associated gastric...

Descripción completa

Detalles Bibliográficos
Autores:	Ettcheto Arriola, Miren, Sánchez-López, E. (Elena), Pons, Laura, Busquets Figueras, Oriol, Olloquequi, Jordi, Beas Zárate, Carlos, Pallàs i Llibería, Mercè, 1964-, García López, María Luisa, Auladell i Costa, M. Carme, Folch, Jaume, Camins Espuny, Antoni
Tipo de recurso:	artículo
Estado:	Versión aceptada para publicación
Fecha de publicación:	2017
País:	España
Institución:	Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:	Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:	oai:recercat.cat:2445/118847
Acceso en línea:	https://hdl.handle.net/2445/118847
Access Level:	acceso abierto
Palabra clave:	Malaltia d'Alzheimer Hipocamp (Cervell) Receptors d'insulina Mitocondris Medicaments Alzheimer's disease Hippocampus (Brain) Insulin receptors Mitochondria Drugs

id	ES_d1f9bc46c904183f5bd4792e0d9b4152
oai_identifier_str	oai:recercat.cat:2445/118847
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Dexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways.Ettcheto Arriola, MirenSánchez-López, E. (Elena)Pons, LauraBusquets Figueras, OriolOlloquequi, JordiBeas Zárate, CarlosPallàs i Llibería, Mercè, 1964-García López, María LuisaAuladell i Costa, M. CarmeFolch, JaumeCamins Espuny, AntoniMalaltia d'AlzheimerHipocamp (Cervell)Receptors d'insulinaMitocondrisMedicamentsAlzheimer's diseaseHippocampus (Brain)Insulin receptorsMitochondriaDrugsThe aim of the present study is to elucidate the neuronal pathways associated to NSAIDs causing a reduction of the risk and progression of Alzheimer's disease. The research was developed administering the active enantiomer of ibuprofen, dexibuprofen (DXI), in order to reduce associated gastric toxicity. DXI was administered from three to six-month-old female APPswe/PS1dE9 mice as a model of familial Alzheimer's disease. DXI treatment reduced the activation of glial cells and the cytokine release involved in the neurodegenerative process, especially TNFα. Moreover, DXI reduced soluble β-amyloid (Aβ1-42) plaque deposition by decreasing APP, BACE1 and facilitating Aβ degradation by enhancing insulin-degrading enzyme. DXI also decreased TAU hyperphosphorylation inhibiting c-Abl/CABLES/p-CDK5 activation signal pathway and prevented spatial learning and memory impairment in transgenic mice. Therefore, chronic DXI treatment could constitute a potential AD-modifying drug, both restoring cognitive functions and reversing multiple brain neuropathological hallmarks.Elsevier B.V.2017201720172017info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersion8 p.application/pdfapplication/pdfhttps://hdl.handle.net/2445/118847Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.1016/j.redox.2017.06.003Redox Biology, 2017, vol. 13, p. 345 -352https://doi.org/10.1016/j.redox.2017.06.003cc-by-nc-nd (c) Elsevier B.V., 2017http://creativecommons.org/licenses/by-nc-nd/3.0/esinfo:eu-repo/semantics/openAccessoai:recercat.cat:2445/1188472026-05-29T05:05:01Z
dc.title.none.fl_str_mv	Dexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways.
title	Dexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways.
spellingShingle	Dexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways. Ettcheto Arriola, Miren Malaltia d'Alzheimer Hipocamp (Cervell) Receptors d'insulina Mitocondris Medicaments Alzheimer's disease Hippocampus (Brain) Insulin receptors Mitochondria Drugs
title_short	Dexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways.
title_full	Dexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways.
title_fullStr	Dexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways.
title_full_unstemmed	Dexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways.
title_sort	Dexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways.
dc.creator.none.fl_str_mv	Ettcheto Arriola, Miren Sánchez-López, E. (Elena) Pons, Laura Busquets Figueras, Oriol Olloquequi, Jordi Beas Zárate, Carlos Pallàs i Llibería, Mercè, 1964- García López, María Luisa Auladell i Costa, M. Carme Folch, Jaume Camins Espuny, Antoni
author	Ettcheto Arriola, Miren
author_facet	Ettcheto Arriola, Miren Sánchez-López, E. (Elena) Pons, Laura Busquets Figueras, Oriol Olloquequi, Jordi Beas Zárate, Carlos Pallàs i Llibería, Mercè, 1964- García López, María Luisa Auladell i Costa, M. Carme Folch, Jaume Camins Espuny, Antoni
author_role	author
author2	Sánchez-López, E. (Elena) Pons, Laura Busquets Figueras, Oriol Olloquequi, Jordi Beas Zárate, Carlos Pallàs i Llibería, Mercè, 1964- García López, María Luisa Auladell i Costa, M. Carme Folch, Jaume Camins Espuny, Antoni
author2_role	author author author author author author author author author author
dc.subject.none.fl_str_mv	Malaltia d'Alzheimer Hipocamp (Cervell) Receptors d'insulina Mitocondris Medicaments Alzheimer's disease Hippocampus (Brain) Insulin receptors Mitochondria Drugs
topic	Malaltia d'Alzheimer Hipocamp (Cervell) Receptors d'insulina Mitocondris Medicaments Alzheimer's disease Hippocampus (Brain) Insulin receptors Mitochondria Drugs
description	The aim of the present study is to elucidate the neuronal pathways associated to NSAIDs causing a reduction of the risk and progression of Alzheimer's disease. The research was developed administering the active enantiomer of ibuprofen, dexibuprofen (DXI), in order to reduce associated gastric toxicity. DXI was administered from three to six-month-old female APPswe/PS1dE9 mice as a model of familial Alzheimer's disease. DXI treatment reduced the activation of glial cells and the cytokine release involved in the neurodegenerative process, especially TNFα. Moreover, DXI reduced soluble β-amyloid (Aβ1-42) plaque deposition by decreasing APP, BACE1 and facilitating Aβ degradation by enhancing insulin-degrading enzyme. DXI also decreased TAU hyperphosphorylation inhibiting c-Abl/CABLES/p-CDK5 activation signal pathway and prevented spatial learning and memory impairment in transgenic mice. Therefore, chronic DXI treatment could constitute a potential AD-modifying drug, both restoring cognitive functions and reversing multiple brain neuropathological hallmarks.
publishDate	2017
dc.date.none.fl_str_mv	2017 2017 2017 2017
dc.type.none.fl_str_mv	info:eu-repo/semantics/article info:eu-repo/semantics/acceptedVersion
format	article
status_str	acceptedVersion
dc.identifier.none.fl_str_mv	https://hdl.handle.net/2445/118847
url	https://hdl.handle.net/2445/118847
dc.language.none.fl_str_mv	Inglés
language_invalid_str_mv	Inglés
dc.relation.none.fl_str_mv	Reproducció del document publicat a: https://doi.org/10.1016/j.redox.2017.06.003 Redox Biology, 2017, vol. 13, p. 345 -352 https://doi.org/10.1016/j.redox.2017.06.003
dc.rights.none.fl_str_mv	cc-by-nc-nd (c) Elsevier B.V., 2017 http://creativecommons.org/licenses/by-nc-nd/3.0/es info:eu-repo/semantics/openAccess
rights_invalid_str_mv	cc-by-nc-nd (c) Elsevier B.V., 2017 http://creativecommons.org/licenses/by-nc-nd/3.0/es
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	8 p. application/pdf application/pdf
dc.publisher.none.fl_str_mv	Elsevier B.V.
publisher.none.fl_str_mv	Elsevier B.V.
dc.source.none.fl_str_mv	Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica) reponame:Recercat. Dipósit de la Recerca de Catalunya instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str	Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str	Recercat. Dipósit de la Recerca de Catalunya
collection	Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869420310068985856
score	15,81155

Dexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways.

Similares en LA Referencia